1. Generics Bulletin
  2. >>Products

Biogen Chases Fresenius After Revealing EU Tocilizumab Nod

Ahead Of CHMP Publication, Firm Announces Positive Opinion For Tofidence Biosimilar

 
• By Dave Wallace

Ahead of the EMA’s CHMP publishing its April meeting highlights, Biogen has revealed a positive opinion for its Tofidence biosimilar tocilizumab rival to RoActemra. However, Fresenius already has a version on the market.

Hand making thumb up painted with flag of European Union
Biogen has revealed a positive CHMP opinion for its tocilizumab biosimilar • Source: Shutterstock

Biogen is next in line for a European biosimilar rival to RoActemra (tocilizumab), with the firm revealing that it has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use for its Tofidence version just ahead of the CHMP publishing its April meeting highlights.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products

J&J Denied Injunction Over Private-Label Ustekinumab In US

 
• By Dave Wallace

Stelara originator J&J has been denied in its initial attempt to prevent Samsung Bioepis and ustekinumab biosimilar partner Sandoz from selling a private-label version of the product through a PBM in the US.

UK Forxiga SPCs Wiped Out As Trio Succeed With Plausibility Attack

 
• By Dean Rudge

Generic competition to AstraZeneca’s blockbuster SGLT2 inhibitor Forxiga (dapagliflozin) treatment for diabetes may hit England and Wales earlier than 2028 after a pair of SPCs were invalidated following proceedings initiated by a trio of generics manufacturers.

What’s Next? Five Things To Look Out For In May

 
• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for May 2025.